Expression and function of transmembrane protein 106A in lung cancer

doi:10.12092/j.issn.1009-2501.2019.05.008

Abstract

Abstract:

AIM: To investigate the expression of transmembrane protein 106A (TMEM106A) in lung cancer and its relationship with clinicopathological features, and the effect of this molecule on the proliferation of lung cancer cells. METHODS: Thirty-one cases of lung cancer tissues were collected from patients with early stage lung cancer. Tissue RNA was extracted and real-time quantitative PCR was used to detect the relative expression of TMEM106A mRNA in lung cancer tissues and para-cancer tissues. TMEM106A lentiviral expression vector Plenti-UBI/TMEM106A was constructed and transfected into H1299 cells to overexpress TMEM106A. Cell proliferation assay and colony formation assay were used to observe the effect of TMEM106A overexpression on the proliferation of lung cancer H1299 cells.RESULTS:Real-time quantitative PCR (qRT- PCR) showed that the relative expression of TMEM106A gene mRNA in lung cancer tissues was lower than that in the control para-cancer tissues. H1299-TMEM106A，the cell line overexpressed TMEM106A, was successfully constructed. Compared with H1299-control, the expression of TMEM106A in cell line H1299-TMEM106A was significantly increased. The proliferation experiment showed that the high expression of TMEM106A significantly inhibited the proliferation of lung cancer cells. The colony formation assay showed that the colony forming ability of lung cancer cells with high expression of TMEM106A in cell line H1299-TMEM106A was significantly lower than that of H1299-control lung cancer cells (P<0.01). CONCLUSION: TMEM106A can inhibit the proliferation of lung cancer cells.

Key words: lung cancer, TMEM106A

CLC Number:

PAN Huan, ZHOU Yuling, QI Weibo, SHEN Hui, JIN Jing, SHEN Jianfen, MA Xingjie, XU Yufen. Expression and function of transmembrane protein 106A in lung cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 529-534.

References

［1］Isla D, Majem M, Violas N, et al. A consensus statement on the gender perspective in lung cancer［J］. Clin Transl Oncol, 2016, 19(5): 1-9.
［2］陈万青, 孙可欣, 郑荣寿, 等. 2014年中国分地区恶性肿瘤发病和死亡分析［J］. 中国肿瘤, 2018, 23(1): 1-14.
［3］杨付红, 张春娣. 肺癌的研究现状［J］. 中国继续医学教育, 2015, 20(2): 30-31.
［4］Cotter TG. Apoptosis and cancer: the genesis of a research field［J］. Nat Rev Cancer, 2009, 9(7): 501-507.
［5］Hanahan D, Weinberg R. Hallmarks of cancer: the next generation ［J］. Cell, 2011, 144(5): 646-674.
［6］Wood HB. TMEM106B is a susceptibility locus for Ftld ［J］. Nat Rev Neurol, 2010, 6(4): 184.
［7］Finch N,Carrasquillo MM,Baker M,et al.TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers［J］.Neurology,2011,76(5):467-474.
［8］Van dZJ, Van LT, Kleinberger G, et al. TMEM106B is associated with frontotemporal lobar degeneration in a clinically diagnosed patient cohort ［J］. Brain, 2011, 134(2): 808-815.
［9］Xu D, Qu L, Hu J, et al. Transmembrane protein 106A is silenced by promoter region hypermethylation and suppresses gastric cancer growth by inducing apoptosis ［J］. J Cel Mol Med, 2014, 18(8): 1655-1666.
［10］Wu CL, Xu J, Wang H, et al. TMEM106a is a novel tumor suppressor in human renal cancer ［J］. Kid Blood Press Res, 2017, 42(5): 853.
［11］许冬, 姜静远, 许晨彤, 等. 跨膜蛋白TMEM106A诱导肝癌细胞HepG2巨泡样死亡［J］. 中国生物化学与分子生物学报, 2017, 30(1): 44-50.
［12］钟良瑞, 陈华, 景晶, 等. 三叶青黄酮抑制肺癌A549细胞生长与蛋白酶体活性的关系研究［J］. 中国临床药理学与治疗学, 2017, 22(10): 1123-1126.
［13］Elmore S. Apoptosis: a review of programmed cell death ［J］. Toxicol Pathol, 2013, 35: 495-516.
［14］Horvitz HR. Genetic control of programmed cell death in the nematode Caenorhabditis elegans ［J］. Cell, 1986, 44(6): 817-829.
［15］Sager R. Tumor suppressor genes in the cell cycle ［J］. Curr Opin Cell Biol, 1992, 4(2): 155.
［16］Das PM, Singal R. DNA methylation and cancer ［J］. J Clin Oncol, 2004, 22(22): 4632-4642.
［17］Davis CD, Uthus EO. DNA methylation, cancer susceptibility, and nutrient interactions ［J］. Exp Biol Med, 2004, 229(10): 988.
［18］Brown R, Strathdee G. Epigenomics and epigenetic therapy of cancer ［J］. Trend Mol Med, 2002, 8(4): S43-S48.

[1]	YOU Rongli, HUANG Yurong, MAORui, HAI Lina, WANG Yingli, WANG Yan. Mechanism of compound kushen injection in the treatment of lung cancer based on serum metabolomics and network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 988-999.
[2]	HOU Qiong, LIU Fei, CHEN Chuanrong. Immunotherapy combined with anti-angiogenic drugs and chemotherapy in negative driver gene and advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 775-779.
[3]	FU Ting, LI Fang, PAN Dayan, XIA Yuanyuan, ZHANG Qiuyuan. miR-718 from exosomes of lung cancer cells induces angiogenesis by targeting PTEN [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 624-632.
[4]	LI Fei, DING Huiqin, CHEN Mengjing. Isonlosinine induces autophagy of PC9 cells by ERK signaling pathway in lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1235-1240.
[5]	LIU Jiajun, QUE Zujun, TIAN Jianhui. Comparative study on the ability of active ingredients in Jinfukang to decrease neutrophils recruiting by lung cancer circulating tumor cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 1-9.
[6]	SU Yang, ZHOU Feng, DING Jinlei. Effects of esketamine combined with sufentanil on postoperative analgesia and emotion after thoracoscopic radical resection of lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 59-65.
[7]	HUANG Xiaoming, DU Ye, LIN Shaoming, SHEN Guanle. Exploratory study of the influence of respiratory microbiology on the efficacy of PD-1 inhibitors monotherapy for patients with advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 66-74.
[8]	ZHANG Kexin, JIA Wenjing, CUI Jiawen, AO Luyao, ZHOU Fang, WANG Guangji, LIU Jiali. Advances in the research and clinical application of the third generation EGFR TKIs in the treatment of non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1016-1030.
[9]	WANG Lin, LI Chongyang, LI Shuaihu, GAO Shenghan, XU Tian, LI Fei. Research progress on pathogenic fusion gene in lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 877-885.
[10]	ZHAO Ziwen, FAN Fangtian, JIANG Zhijun. Induced bronchial associated lymphoid tissue (iBALT) formation and research of related lung diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 353-360.
[11]	CUI Hua, YAN Hongxia, YIN Mei. Effects of down-regulating lncRNA LINC00176 on cisplatin resistance and autophagy in lung cancer A549/DDP cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 616-623.
[12]	HUANG Yiting, SHEN Aizong. Clinical research progress of afatinib therapy for lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 474-480.
[13]	PEI Qinghua, SUN Jianli. Research progress of Osimertinib acquired resistance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 105-112.
[14]	WEI Weitian, CHEN Sheng, WANG Liang, ZENG Jian. Breviscapine induced the apoptosis of non-small cell lung cancer A549 cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 618-624.
[15]	YANG Guoliang, HU Dandan, XU Yikai, LOU Liming. Yiqi Huoxue decoction inhibits malignant biological behavior of human lung cancer cells via the miR-21/PTEN signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 512-518.